Robert Howard

Robert Howard

Auto-generated profile, based on publicly available information

Robert Howard

University College London

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in The Lancet
Verified
Journal Article
Closed access
GLGill Livingston
Gill Livingston
ASAndrew Sommerlad
Andrew Sommerlad
VOVasiliki Orgeta
Vasiliki Orgeta
SCSergi G Costafreda
Sergi G Costafreda
JHJonathan Huntley
Jonathan Huntley
NMNaaheed Mukadam
Naaheed Mukadam

1 March 1996 in Magnetic Resonance in Medicine
Verified
Journal Article
Closed access
PDF file
KFKarl Friston Friston
Karl Friston Friston
SWSteven Williams
Steven Williams
RHRobert Howard
Robert Howard
RFRichard S. J. Frackowiak
Richard S. J. Frackowiak
RTRobert Turner
Robert Turner

1 September 2002 in NeuroImage
Verified
Journal Article
Closed access
MCMarco Cataniab
Marco Cataniab
RHRobert J. Howard
Robert J. Howard
SPSinisa Pajevicc
Sinisa Pajevicc
DJDerek K. Jones
Derek K. Jones

20 April 2010 in Nature
Verified
Journal Article
Open access
PDF file
AOAdrian M. Owen
Adrian M. Owen
AHAdam Hampshire
Adam Hampshire
JGJessica Adrienne Grahn
Jessica Adrienne Grahn
RSRobert Stenton
Robert Stenton
SDSaid Dajani
Said Dajani
CBClive Mr. Ballard
Clive Mr. Ballard
Although the public spends millions of pounds per year on various 'brain training' programs, the efficacy and performance of these training regimes remain unclear. In a collaboration with the BBC science series Bang Goes The Theory, Adrian Owen and colleagues conducted a six-week trial of various online training regimes. And although they observed improvements on the specific tasks used for training, the authors concluded that any improvements failed to transfer to other untrained cognitive tasks. Millions of pounds per year are spent on various 'brain-training' programs; however, the efficacy and performance of these training regimes is still unclear. In collaboration with the BBC, a six-week online study of brain training was conducted. Although improvements were observed in the specific tasks used for training, in the authors' view there was no evidence that these improvements transferred to other untrained cognitive tasks. ‘Brain training’, or the goal of improved cognitive function through the regular use of computerized tests, is a multimillion-pound industry1, yet in our view scientific evidence to support its efficacy is lacking. Modest effects have been reported in some studies of older individuals2,3 and preschool children4, and video-game players outperform non-players on some tests of visual attention5. However, the widely held belief that commercially available computerized brain-training programs improve general cognitive function in the wider population in our opinion lacks empirical support. The central question is not whether performance on cognitive tests can be improved by training, but rather, whether those benefits transfer to other untrained tasks or lead to any general improvement in the level of cognitive functioning. Here we report the results of a six-week online study in which 11,430 participants trained several times each week on cognitive tasks designed to improve reasoning, memory, planning, visuospatial skills and attention. Although improvements were observed in every one of the cognitive tasks that were trained, no evidence was found for transfer effects to untrained tasks, even when those tasks were cognitively closely related.

8 March 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
RHRobert Howard
Robert Howard
RMRupert McShane
Rupert McShane
JLJames Lindesay
James Lindesay
CRCraig Ritchie
Craig Ritchie
ABAshley Baldwin
Ashley Baldwin
PPPatrick Phillips
Patrick Phillips
Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease. We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini–Mental State Examination [SMMSE, on which scores range from 0 to 30, with higher scores indicating better cognitive function]) to continue donepezil, discontinue donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine. Patients received the study treatment for 52 weeks. The coprimary outcomes were scores on the SMMSE and on the Bristol Activities of Daily Living Scale (BADLS, on which scores range from 0 to 60, with higher scores indicating greater impairment). The minimum clinically important differences were 1.4 points on the SMMSE and 3.5 points on the BADLS. Patients assigned to continue donepezil, as compared with those assigned to discontinue donepezil, had a score on the SMMSE that was higher by an average of 1.9 points (95% confidence interval [CI], 1.3 to 2.5) and a score on the BADLS that was lower (indicating less impairment) by 3.0 points (95% CI, 1.8 to 4.3) (P<0.001 for both comparisons). Patients assigned to receive memantine, as compared with those assigned to receive memantine placebo, had a score on the SMMSE that was an average of 1.2 points higher (95% CI, 0.6 to 1.8; P<0.001) and a score on the BADLS that was 1.5 points lower (95% CI, 0.3 to 2.8; P=0.02). The efficacy of donepezil and of memantine did not differ significantly in the presence or absence of the other. There were no significant benefits of the combination of donepezil and memantine over donepezil alone. In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months. (Funded by the U.K. Medical Research Council and the U.K. Alzheimer's Society; Current Controlled Trials number, ISRCTN49545035.)

1 February 2000 in American Journal of Psychiatry
Verified
Journal Article
Closed access
RHR Howard
R Howard
PRP V Rabins
P V Rabins
MSM V Seeman
M V Seeman
DJD V Jeste
D V Jeste